Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Net Income (2019 - 2025)

Benitec Biopharma's Net Income history spans 7 years, with the latest figure at -$9.4 million for Q1 2025.

  • For Q1 2025, Net Income fell 125.93% year-over-year to -$9.4 million; the TTM value through Mar 2025 reached -$29.2 million, down 35.54%, while the annual FY2024 figure was -$21.6 million, 12.93% down from the prior year.
  • Net Income for Q1 2025 was -$9.4 million at Benitec Biopharma, up from -$10.0 million in the prior quarter.
  • Across five years, Net Income topped out at -$3.5 million in Q1 2022 and bottomed at -$10.0 million in Q4 2024.
  • The 5-year median for Net Income is -$4.7 million (2022), against an average of -$5.3 million.
  • The largest annual shift saw Net Income grew 11.79% in 2024 before it plummeted 125.93% in 2025.
  • A 5-year view of Net Income shows it stood at -$4.8 million in 2021, then fell by 15.95% to -$5.6 million in 2022, then fell by 23.38% to -$6.9 million in 2023, then tumbled by 43.98% to -$10.0 million in 2024, then increased by 6.18% to -$9.4 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Net Income are -$9.4 million (Q1 2025), -$10.0 million (Q4 2024), and -$5.2 million (Q3 2024).